

### Malawi

# Support for Vaccine: DTP-HepB-Hib This Decision Letter sets out the Programme Terms of a Programme.

| 1.  | Country:   | Malawi        |                       |   |   |              |              |                    |
|-----|--|---------------|-----------------------|---|---|--------------|--------------|--------------------|
| 2.  | Vaccine drant nilmner  |               |                       | 0715-MWI-04A-X, 1315-MWI-04c-X, 16-MWI-04c-X,<br>1720-MWI-04c-X |   |              |              |                    |
| 3.  | Date of Decision Letter: 10 September 2019   |               |                       |   |   |              |              |                    |
| 4.  | Date of the Partnership Framework Agreement: 29 October 2013   |               |                       |   |   |              |              |                    |
| 5.  | Programme title: New Vaccine Support (NVS), DTP-HepB-Hib, Routine  |               |                       |   |   |              |              |                    |
| 6.  | Vaccine type: DTP-HepB-H   |               |                       |   |   |              |              |                    |
| 7.  | Requested product presentation and formulation of vaccine:   |               |                       |   |   |              |              |                    |
|     | Penta, 10 dose(s) per vial, LIQUID   |               |                       |   |   |              |              |                    |
| 8.  | Programme Duration: 2002-2020  |               |                       |   |   |              |              |                    |
| 9.  | Programme Budget (indicative): <sup>2</sup> (subject to the terms of the Partnership Framework Agreement, if applicable) |               |                       |   |   | greement, if |              |                    |
|     |  | 2002-2018     | 2019                  | 2020  | 2021  | 2022         | 2023         | Total <sup>2</sup> |
| 8   | Programme<br>Budget<br>(US\$)  | 90,277,382    | 1,173,000             | 1,226,500   |   | - V 1 2      |              | 92,676,882         |
| 10. | Vaccine introduction grant   |               |                       |   |   |              |              |                    |
|     | Not applicable   |               |                       |   |   |              |              |                    |
| 11. | Product switch grant  Not applicable   |               |                       |   |   |              |              |                    |
| 12. | 그  |               |                       |   | ubject to the terms of the Partnership Framework Agreement, if oplicable) |              |              |                    |
|     | Type of supplies to be<br>purchased with Gavi<br>funds   |               |                       | 2002-2018   |   | 2019         |              |                    |
|     | Number of  | vaccine doses |                       |   |   | 1,648,000    |              |                    |
|     |  | mounts (US\$) |                       | 90,277,382  |   | 1,173,000    |              |                    |
| 13. | Procuremen   |               | UNICEF. Th<br>UNICEF. | e Country sha   | all release its   |              | payments eac | h year to          |
| 14. | Self-procure   | ment:         | Not applicabl         | e   | 26  |              |              |                    |

 <sup>&</sup>lt;sup>1</sup> This is the entire duration of the programme.
 <sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.
 <sup>3</sup> This is the amount that Gavi has approved.



## 15. Co-financing obligations:

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

| Type of supplies to be purchased with Country funds in each year | 2019    |
|--|---------|
| Number of vaccine doses  | 645,000 |
| Number of AD syringes  | -       |
| Number of re-constitution syringes                               | -       |
| Number of safety boxes   | -       |
| Value of vaccine doses (US\$)                                    | 444,841 |
| Total co-financing payments (US\$)<br>(including freight)        | 459,000 |

### 16. Operational support for catch-up campaigns:

Not applicable

### 17. Additional Reporting Requirements:

|   |   | Due dates             |  |
|---|---|-----------------------|--|
|   | or the annual procurement of vaccines, Country shall submit the ormation each year:   |                       |  |
| •   | vaccine stock levels including buffer stock, by end of March;   | 31 March              |  |
| •   | number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. | 15 May                |  |
| •   | Countries shall report the actual switch date in the first renewal request following the actual implementation.   | ad of memory to early |  |
|   |   | Productive formation  |  |
| In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.  To be agreed with Gavi Secretariat |   |                       |  |



| 18. | Financial clarifications:         | Country shall provide the following clarifications to Gavi*: |
|-----|-----------------------------------|--|
|     | Not applicable                    |  |
| 19. | Other conditions:  Not applicable |  |

Signed by,

On behalf of Gavi

Thabani Maphosa,

Managing Director, Country Programmes

10 September 2019